Familial amyloidosis laboratory findings: Difference between revisions
Farima Kahe (talk | contribs) |
Farima Kahe (talk | contribs) |
||
| Line 50: | Line 50: | ||
==Laboratory Findings== | ==Laboratory Findings== | ||
Cardiac | '''Cardiac''' | ||
* [[Cardiac biomarkers]] are the most important predictors of outcome in amyloidosis. | * [[Cardiac biomarkers]] are the most important predictors of outcome in amyloidosis. | ||
| Line 59: | Line 59: | ||
:* BNP and NT-proBNP | :* BNP and NT-proBNP | ||
Hepatic | '''Hepatic''' | ||
* [[Liver function tests]], including: | * [[Liver function tests]], including: | ||
| Line 69: | Line 69: | ||
:*Albumin | :*Albumin | ||
Renal | '''Renal''' | ||
* A variety of kidney function tests can suggest amyloidosis. | * A variety of kidney function tests can suggest amyloidosis. | ||
* These [[Test|tests]] include abnormalities in: | * These [[Test|tests]] include abnormalities in: | ||
| Line 78: | Line 79: | ||
:*[[Albumin]] to [[creatinine]] ratio in the [[urine]] | :*[[Albumin]] to [[creatinine]] ratio in the [[urine]] | ||
Thyroid | '''Thyroid''' | ||
* Common [[Test|tests]] that are abnormal in thyroidal involvement of amyloidosis include: | * Common [[Test|tests]] that are abnormal in thyroidal involvement of amyloidosis include: | ||
| Line 84: | Line 86: | ||
:*Free T4 | :*Free T4 | ||
Bone marrow | '''Bone marrow''' | ||
* Concurrent [[multiple myeloma]] can be found in [[Patient|patients]] with amyloidosis. | * Concurrent [[multiple myeloma]] can be found in [[Patient|patients]] with amyloidosis. | ||
* In such cases, [[laboratory]] [[Test|testing]] should include<ref name="pmid24145344">{{cite journal| author=Kourelis TV, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR et al.| title=Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. | journal=J Clin Oncol | year= 2013 | volume= 31 | issue= 34 | pages= 4319-24 | pmid=24145344 | doi=10.1200/JCO.2013.50.8499 | pmc=4881366 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24145344 }} </ref>: | * In such cases, [[laboratory]] [[Test|testing]] should include<ref name="pmid24145344">{{cite journal| author=Kourelis TV, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR et al.| title=Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. | journal=J Clin Oncol | year= 2013 | volume= 31 | issue= 34 | pages= 4319-24 | pmid=24145344 | doi=10.1200/JCO.2013.50.8499 | pmc=4881366 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24145344 }} </ref>: | ||
Revision as of 18:17, 30 October 2019
|
Familial amyloidosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Familial amyloidosis laboratory findings On the Web |
|
American Roentgen Ray Society Images of Familial amyloidosis laboratory findings |
|
Risk calculators and risk factors for Familial amyloidosis laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].
OR
Laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
OR
[Test] is usually normal for patients with [disease name].
OR
Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].
OR
There are no diagnostic laboratory findings associated with [disease name].
Laboratory Findings
There are no diagnostic laboratory findings associated with [disease name].
OR
An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].
OR
[Test] is usually normal among patients with [disease name].
OR
Laboratory findings consistent with the diagnosis of [disease name] include:
- [Abnormal test 1]
- [Abnormal test 2]
- [Abnormal test 3]
OR
Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].
Overview
Laboratory findings in amyloidosis include elevated erythrocyte sedimentation rate, increased BUN level, serum creatinine, protein, casts, or fat bodies in urine. Serum troponin, B-type natriuretic peptide, and beta-2-microglobulin are prognostic markers for heart failure. Amyloid deposits can be identified histologically by Congo red staining and viewing under polarized light where amyloid deposits produce a distinctive 'apple green birefringence'. Alternatively, thioflavin T stain may be used. An abdominal fat pad aspiration, rectal mucosa biopsy, or bone marrow biopsy can help confirm the diagnosis. They reveal positive findings in 80% patients.
Laboratory Findings
Cardiac
- Cardiac biomarkers are the most important predictors of outcome in amyloidosis.
- They provide a quantitative assessment for cardiac damage and wall strain.[1]
- The biomarkers include:
- Troponin I or Troponin T
- BNP and NT-proBNP
Hepatic
- Liver function tests, including:
- AST
- ALT
- Total bilirubin
- Alkaline phosphatase
- Albumin
Renal
- A variety of kidney function tests can suggest amyloidosis.
- These tests include abnormalities in:
- Serum creatinine
- Urinary protein
- Glomerular filtration rate
- Albumin to creatinine ratio in the urine
Thyroid
- Common tests that are abnormal in thyroidal involvement of amyloidosis include:
- TSH
- Free T4
Bone marrow
- Concurrent multiple myeloma can be found in patients with amyloidosis.
- In such cases, laboratory testing should include[2]:
- Serum protein electrophoresis
- Immunoglobulin levels
- Serum free light chains
- Beta-2-microglobulin
References
- ↑ Merlini G, Seldin DC, Gertz MA (May 2011). "Amyloidosis: pathogenesis and new therapeutic options". J. Clin. Oncol. 29 (14): 1924–33. doi:10.1200/JCO.2010.32.2271. PMC 3138545. PMID 21483018.
- ↑ Kourelis TV, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR; et al. (2013). "Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis". J Clin Oncol. 31 (34): 4319–24. doi:10.1200/JCO.2013.50.8499. PMC 4881366. PMID 24145344.